Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study

BACKGROUND: Tabalumab is a human monoclonal antibody that neutralises B-cell activating factor. OBJECTIVES: To evaluate tabalumab efficacy and safety in patients with rheumatoid arthritis (RA). METHODS: This phase 3, randomised, double-blind, placebo-controlled study evaluated 456 patients with acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiff, Michael, Combe, Bernard, Dörner, Thomas, Kremer, Joel M, Huizinga, Thomas W, Veenhuizen, Melissa, Gill, Anne, Komocsar, Wendy, Berclaz, Pierre-Yves, Ortmann, Robert, Lee, Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623366/
https://www.ncbi.nlm.nih.gov/pubmed/26535134
http://dx.doi.org/10.1136/rmdopen-2014-000037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623366/
https://www.ncbi.nlm.nih.gov/pubmed/26535134
http://dx.doi.org/10.1136/rmdopen-2014-000037

Ejemplares similares